Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation.
busulfan
myelofibrosis
population pharmacokinetics
sulfolane
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
27 May 2022
27 May 2022
Historique:
received:
27
04
2022
revised:
18
05
2022
accepted:
25
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment to date. Busulfan-based conditioning regimens are commonly used, although high inter-individual variability (IIV) in busulfan drug exposure makes individual dose selection challenging. Since data regarding the IIV in patients with myelofibrosis are sparse, this study aimed to develop a population pharmacokinetic (PopPK) model of busulfan and its metabolite sulfolane in patients with myelofibrosis. The influence of patient-specific covariates on the pharmacokinetics of drug and metabolite was assessed using non-linear mixed effects modeling in NONMEM
Identifiants
pubmed: 35745718
pii: pharmaceutics14061145
doi: 10.3390/pharmaceutics14061145
pmc: PMC9229330
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmaceutics. 2022 Mar 15;14(3):
pubmed: 35336021
J Clin Pharmacol. 2018 Sep;58(9):1196-1204
pubmed: 29663421
Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208
pubmed: 30930192
Biol Blood Marrow Transplant. 2012 Jun;18(6):944-50
pubmed: 22155501
Clin Pharmacokinet. 2021 Jan;60(1):17-51
pubmed: 33128207
Clin Microbiol Infect. 2019 Oct;25(10):1286.e1-1286.e7
pubmed: 30872102
Blood. 2014 Aug 14;124(7):1062-9
pubmed: 24986690
Blood. 2010 Mar 4;115(9):1703-8
pubmed: 20008785
Transplant Cell Ther. 2022 Feb;28(2):104.e1-104.e7
pubmed: 34883294
Leukemia. 2017 Dec;31(12):2726-2731
pubmed: 28561069
Pharmacogenomics. 2015;16(14):1585-94
pubmed: 26419450
Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69
pubmed: 19611402
Clin Pharmacokinet. 2020 Aug;59(8):1049-1061
pubmed: 32157629
Bone Marrow Transplant. 2017 Apr;52(4):580-587
pubmed: 27991894
Pharmacogenetics. 2001 Nov;11(8):663-9
pubmed: 11692074
Clin Cancer Res. 2011 Nov 1;17(21):6867-77
pubmed: 21918171
Bone Marrow Transplant. 2011 Nov;46(11):1418-25
pubmed: 21132026
Br J Haematol. 2020 Aug;190(3):437-441
pubmed: 32108327
Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925
pubmed: 27481448
Biol Blood Marrow Transplant. 2020 Aug;26(8):1439-1445
pubmed: 32438043
Clin Cancer Res. 2014 Feb 1;20(3):754-63
pubmed: 24218510
Oncotarget. 2017 Aug 27;8(53):90852-90867
pubmed: 29207608
Blood. 2014 Jun 12;123(24):3714-9
pubmed: 24786775
Transplant Cell Ther. 2022 Feb;28(2):115.e1-115.e5
pubmed: 34775147
Lancet Haematol. 2016 Nov;3(11):e526-e536
pubmed: 27746112
Comput Methods Programs Biomed. 2011 Jan;101(1):72-9
pubmed: 20627442
AAPS J. 2011 Jun;13(2):143-51
pubmed: 21302010
J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):583-596
pubmed: 27730482
AAPS J. 2009 Sep;11(3):558-69
pubmed: 19649712
CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1043-1056
pubmed: 34453497
Clin Pharmacokinet. 2012 May 1;51(5):331-45
pubmed: 22455797
Bone Marrow Transplant. 2019 Feb;54(2):204-211
pubmed: 29795431
AAPS J. 2011 Sep;13(3):390-404
pubmed: 21618059
Pharmacogenomics J. 2014 Jun;14(3):263-71
pubmed: 24165757
Ther Drug Monit. 2008 Aug;30(4):504-10
pubmed: 18641537
Ther Drug Monit. 2015 Apr;37(2):236-45
pubmed: 25162216
Biol Blood Marrow Transplant. 2012 Oct;18(10):1589-99
pubmed: 22531490
Br J Clin Pharmacol. 2018 Jul;84(7):1494-1504
pubmed: 29469189
Blood. 2009 Dec 17;114(26):5264-70
pubmed: 19812383
J Oncol Pract. 2016 Jul;12(7):611-21
pubmed: 27407157